Viatris Corp - VTRS Forward P/S Multiple

Viatris Corp - graphic logo of issuer VTRS

Viatris Inc. is expanding its portfolio through biotech partnerships and global licensing. Balance sheet deleveraging and the launch of complex biosimilars are driving growth. The P/S forward valuation history on the GURU.Markets chart clearly demonstrates market expectations, where the 1.60 level captures recent values. Stable cash flow from core brands supports the company while new growth catalysts emerge.

VTRS (viatris.com) Price-to-Projected Revenue Ratio history from 07/04/2022 to 11/15/2026

Metric breakdowns and analytics for Viatris (VTRS)

- market price and analyst price targets:
General company analysis:VTRS (Viatris Corp)
Product sample of viatris.com

Viatris Inc. (VTRS) expansion into emerging markets and complex therapeutic niches is directly reflected in the forward P/S history. This indicator compares the company's current market value with expected annual revenue, transforming analyst forecasts into a daily trend. A declining multiple amid stable sales may signal that assets are undervalued against the backdrop of a maturing branded generics market.